Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2013-04-01

Last Posted Date: 2017-08-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 64

Registration Number: NCT01821846

Locations: 🇰🇷
Novo Nordisk Investigational Site, Wonju, Korea, Republic of

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Faster-acting insulin aspart
Drug: Insulin aspart
Drug: Insulin glargine

First Posted Date: 2013-03-27

Last Posted Date: 2019-01-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 881

Registration Number: NCT01819129

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/insulin aspart
Drug: insulin degludec
Drug: insulin aspart

First Posted Date: 2013-03-19

Last Posted Date: 2017-03-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01814137

Locations: 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin 287
Drug: insulin glargine
Drug: placebo

First Posted Date: 2013-03-12

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 84

Registration Number: NCT01809184

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin 338 (GIPET I)
Drug: insulin glargine
Drug: placebo

First Posted Date: 2013-02-21

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01796366

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Other: glucose clamp

First Posted Date: 2013-02-12

Last Posted Date: 2018-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 29

Registration Number: NCT01789593

Locations: 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark

A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2013-02-11

Last Posted Date: 2016-12-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT01789086

Locations: 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany

A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Other: glucose clamp

First Posted Date: 2013-01-31

Last Posted Date: 2017-01-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 26

Registration Number: NCT01780272

Locations: 🇩🇰
Novo Nordisk Investigational Site, Glostrup, Denmark

Treatment of Congenital Factor VII Deficiency

Completed

Conditions: Congenital FVII Deficiency
Congenital Bleeding Disorder

Interventions: Drug: activated recombinant human factor VII
Drug: Fresh frozen plasma (Source unspecified)
Drug: Plasma-derived FVII (LFB)
Drug: Prothrombin Complex conc. (PCC)
Drug: Plasma-derived FVII conc. (pdFVII Baxter)
Drug: Plasma-derived FVII conc. (pdFVII PFL)

First Posted Date: 2013-01-30

Last Posted Date: 2017-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 163

Registration Number: NCT01779921

Locations: 🇻🇪
Novo Nordisk Investigational Site, Caracas, Venezuela

Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature

Phase 3

Completed

Conditions: Idiopathic Short Stature
Growth Disorder

Interventions: Drug: somatropin

First Posted Date: 2013-01-29

Last Posted Date: 2017-06-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 54

Registration Number: NCT01778023

Locations: 🇰🇷
Novo Nordisk Investigational Site, Suwon, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy